Department of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece; German Aortic Center Hamburg, Department of Vascular Medicine, University Heart and Vascular Center UKE Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Vascular Surgery, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
J Vasc Surg. 2021 Dec;74(6):2104-2113.e7. doi: 10.1016/j.jvs.2021.06.032. Epub 2021 Jun 29.
The aim of our systematic review and meta-analysis was to assess the effect of accessory renal artery (ARA) coverage on renal function in terms of acute kidney injury (AKI), renal infarction, chronic renal failure (CRF), and mortality in patients undergoing standard endovascular aortic aneurysm repair (EVAR) or endovascular repair of complex aneurysms.
An electronic search of the English language medical literature from 2000 to September 2020 was conducted using the MEDLINE, EMBASE, and Cochrane databases with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) method for studies reporting on ARA management in patients undergoing endovascular repair of aneurysms in the abdominal and thoracoabdominal aorta. The patients were divided into two groups: group 1, patients with ARA coverage; and group 2, patients without an ARA or without coverage of the ARA. Each group included two arms, one of patients who had undergone standard EVAR and one of patients who had undergone endovascular treatment of a complex aortic aneurysm. The GRADE (grading of recommendations assessment, development, evaluation) approach was used to evaluate the quality of evidence and summary of the findings. The primary outcomes included the incidence of AKI, renal infarction, CRF, and mortality.
Ten retrospective, nonrandomized, control studies were included in the systematic review reporting on 1014 patients (302 with a covered ARA vs 712 without an ARA or without ARA coverage). In six studies, the mean diameter of the covered ARA was <4 mm (range, 2.7-3.4 mm). The mean follow-up was 22.74 months (range, 1-42 months). In the standard EVAR subgroup, the risk of AKI (odds ratio [OR], 0.72; 95% confidence interval [CI], 0.21-2.51; I = 0%] in the early period, and CRF (OR, 4.44; 95% CI, 0.46-42.61; I = 87%) and death (OR, 0.91; 95% CI, 0.36-2.31; I = 0%) during follow-up were similar between groups 1 and 2. Only the risk of renal infarction was greater in group 1 than in group 2 (OR, 93.3; 95% CI, 1.48-5869; I = 92%). In the complex aneurysm repair subgroup, the risk of AKI (OR, 1.85; 95% CI, 0.61-5.64; I = 42%) in early period and CRF (OR, 1.64; 95% CI, 0.88-3.07; I = not applicable) and death (OR, 3.63; 95% CI, 0.14-96.29; I = 56%) during follow-up were similar between groups 1 and 2. Only the risk of renal infarction was greater for group 1 compared with group 2 (OR, 8.58; 95% CI, 4.59-16.04; I = 0%).
ARA (<4 mm) coverage in patients undergoing standard EVAR or endovascular repair of complex aneurysms is associated with an increased risk of renal infarction. However, we found no clinical effects of ARA coverage on renal function or mortality in early postoperative and follow-up period. Preservation of an ARA >4 mm should be considered.
我们的系统评价和荟萃分析的目的是评估在接受标准血管内腹主动脉瘤修复(EVAR)或复杂动脉瘤的血管内修复的患者中,辅助肾动脉(ARA)覆盖对急性肾损伤(AKI)、肾梗死、慢性肾衰竭(CRF)和死亡率的影响。
使用 MEDLINE、EMBASE 和 Cochrane 数据库,采用 PRISMA(系统评价和荟萃分析的首选报告项目)方法,对 2000 年至 2020 年 9 月期间发表的英语医学文献进行电子检索,以报告腹主动脉和胸腹主动脉动脉瘤血管内修复患者的 ARA 管理情况。患者分为两组:组 1,接受 ARA 覆盖的患者;组 2,未接受 ARA 或未覆盖 ARA 的患者。每组包括两个亚组,一组为接受标准 EVAR 的患者,一组为接受复杂主动脉瘤血管内治疗的患者。使用 GRADE(推荐评估、制定、评价)方法评估证据质量和总结发现。主要结局包括 AKI、肾梗死、CRF 和死亡率的发生率。
10 项回顾性、非随机、对照研究纳入了 1014 名患者(302 名接受覆盖 ARA 治疗,712 名未接受 ARA 或未覆盖 ARA)的系统评价报告。在 6 项研究中,覆盖的 ARA 的平均直径<4mm(范围 2.7-3.4mm)。平均随访时间为 22.74 个月(范围 1-42 个月)。在标准 EVAR 亚组中,早期 AKI(比值比 [OR],0.72;95%置信区间 [CI],0.21-2.51;I = 0%)和 CRF(OR,4.44;95%CI,0.46-42.61;I = 87%)和随访期间的死亡率(OR,0.91;95%CI,0.36-2.31;I = 0%)在组 1 和组 2 之间相似。只有组 1 的肾梗死风险高于组 2(OR,93.3;95%CI,1.48-5869;I = 92%)。在复杂动脉瘤修复亚组中,早期 AKI(OR,1.85;95%CI,0.61-5.64;I = 42%)和 CRF(OR,1.64;95%CI,0.88-3.07;I =不适用)和随访期间的死亡率(OR,3.63;95%CI,0.14-96.29;I = 56%)在组 1 和组 2 之间相似。只有组 1 的肾梗死风险高于组 2(OR,8.58;95%CI,4.59-16.04;I = 0%)。
在接受标准 EVAR 或复杂动脉瘤血管内修复的患者中,<4mm 的 ARA 覆盖与肾梗死风险增加相关。然而,我们没有发现 ARA 覆盖对术后早期和随访期间肾功能或死亡率的临床影响。应考虑保留>4mm 的 ARA。